Drug intelligence / Profile preview

HUC2-694

Development stage: Preclinical
Lead developer: Huons
Modality: Small Molecules
Administration: Oral

Overview

**HUC2-694** is a Huons preclinical small-molecule antihypertensive candidate. Huons classifies its intended pharmacology as an angiotensin receptor blocker, calcium channel blocker, and diuretic approach, designed to lower blood pressure through complementary effects on vascular tone and fluid balance. The exact active constituent or constituents, specific molecular targets, formulation, and route of administration have not been publicly disclosed.

Targets

AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on HUC2-694.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUC2-694.

Explore the full profile